πŸ‡ΊπŸ‡Έ FDA
Patent

US 12336995

Combination therapies

granted A61KA61K31/517A61K31/519

Quick answer

US patent 12336995 (Combination therapies) held by Mirati Therapeutics, Inc. expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Mirati Therapeutics, Inc.
Grant date
Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61K, A61K31/517, A61K31/519, A61K31/5377, A61K31/5386